Valuation: Sanofi India Limited

Capitalization 76.64B 812M 689M 631M 596M 1.11B 1.12B 7.48B 2.92B 36.81B 3.04B 2.98B 127B P/E ratio 2026 *
19.2x
P/E ratio 2027 * 17.9x
Enterprise value 76.64B 812M 689M 631M 596M 1.11B 1.12B 7.48B 2.92B 36.81B 3.04B 2.98B 127B EV / Sales 2026 *
3.93x
EV / Sales 2027 * 3.69x
Free-Float
39.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.79%
1 week-3.89%
Current month-4.10%
1 month-5.69%
3 months-19.46%
6 months-28.75%
Current year-20.12%
1 week 3,256.7
Extreme 3256.7
3,439.6
1 month 3,256.7
Extreme 3256.7
3,614.65
Current year 3,151.05
Extreme 3151.05
4,239.3
1 year 3,151.05
Extreme 3151.05
6,399.95
3 years 3,151.05
Extreme 3151.05
10,526.05
5 years 3,151.05
Extreme 3151.05
10,526.05
10 years 3,151.05
Extreme 3151.05
10,526.05
Manager TitleAgeSince
Chief Executive Officer - 2025-10-26
Chief Executive Officer 51 2025-07-20
Compliance Officer - 2025-09-30
Director TitleAgeSince
Chairman 68 2026-04-29
Director/Board Member 53 2021-02-22
Director/Board Member 51 2023-11-30
Change 5d. change 1-year change 3-years change Capi.($)
-1.79%-3.89%-44.18%-47.37% 812M
+1.34%+2.70%+11.06%+94.86% 46.95B
-0.32%-2.40%+64.15%+134.03% 37.06B
-3.13%-2.25%-13.67%+38.29% 11.52B
+1.80%+6.05%+8.15%+86.27% 10.02B
+1.31%+2.05%+40.68%+121.33% 8.88B
-5.62%-6.61%+17.11%+37.64% 7.85B
-0.32%-0.71%+19.15%+52.17% 7.67B
-0.75%+4.30%+62.99%-3.87% 7.44B
-0.81%-1.94%+69.88%+304.60% 7.07B
Average -0.82%+0.26%+23.53%+81.80% 14.53B
Weighted average by Cap. -0.10%+0.65%+30.22%+100.40%

Financials

2026 *2027 *
Net sales 19.51B 207M 175M 161M 152M 283M 285M 1.91B 743M 9.37B 775M 759M 32.35B 20.79B 220M 187M 171M 162M 301M 304M 2.03B 792M 9.99B 826M 809M 34.48B
Net income 3.99B 42.28M 35.93M 32.88M 31.03M 57.88M 58.4M 390M 152M 1.92B 159M 155M 6.62B 4.28B 45.28M 38.47M 35.2M 33.23M 61.98M 62.53M 418M 163M 2.05B 170M 166M 7.09B
Net Debt - -
Logo Sanofi India Limited
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
Employees
1,097
Date Price Change Volume
26-05-11 3,268.25 -1.79% 1,669
26-05-08 3,327.85 -1.90% 2,815
26-05-07 3,392.35 -0.14% 1,070
26-05-06 3,396.95 -0.17% 963
26-05-05 3,402.85 +0.07% 453
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 500674 Stock